source
- Hims & Hers pivots to branded GLP-1 drugs after striking deal with Eli LillyHims & Hers, which previously emphasized personalized care through compounded products, is changing its business model. The company is now focusing on established brand-name GLP-1 treatments rathe…
- Bayer's asundexian receives FDA approval for stroke preventionBayer announced that the U.S. Food and Drug Administration has approved its oral anticoagulant asundexian for stroke prevention. The drug is indicated to lower the risk of subsequent stroke in pati…